

Supplemental material

New shuttle vectors for gene cloning and expression in multidrug-resistant *Acinetobacter* species

by Massimiliano Lucidi, Federica Runci, Giordano Rampioni, Emanuela Frangipani, Livia Leoni and Paolo Visca

Including figures S1, S2, S3, S4, S5, S6, S7 and tables S1 and S2




FIG S1 Schematic representation of cloning steps in pVRL1 construction. (A) pWH1266 was digested at PvuII restriction sites to obtain the 4,693-bp replication and maintenance region for *A. baumannii*. This region contains the oriAb (violet), *paaA2*-like antitoxin gene (orange), *parE2*-like toxin gene (light purple) and the *nickase*-like gene (cyan). The 4,693-bp fragment was then cloned into the SmaI site of pBS, to obtain pBSoriAb (B). The Gm-resistance cassette (green) was amplified by PCR from pEX19Gm (C), while the ColE1-like origin of replication (yellow) and the MCS within the *lacZα* gene (grey), were amplified by PCR from pBS (D). Amplicons with artificially-introduced restriction sites (Table S1) are shown as external arcs of circle. The oriAb fragment was obtained from pBSoriAb by digestion with BamHI and PstI, while the amplicons derived from pBS and pEX19Gm were digested with BclI/NcoI and NcoI/NsiI, respectively. All the three DNA digestion products were directionally ligated to obtain the pVRL1 vector (E), since BclI-BamHI and NsiI-PstI generate compatible cohesive ends. The relevant features of each plasmid are indicated with colours. Unique cutter restriction enzymes are highlighted in bold. All genes are reported in scale over the total length of the vector. Image obtained by Snapgene software (from GSL Biotech; available at snapgene.com).




FIG S2 Blue/white screening for the detection in *E. coli* DH5 α carrying the *trpE*_{wt} gene in pVRL1. The *trpE*_{wt} gene was amplified from *A. baumannii* ATCC19606^T genome and then cloned into the MCS of the pVRL1 plasmid. All white colonies screened contained the *trpE*_{wt} gene, whereas blue colonies did not. Clones were screened with both PCR and analytic digestion (data not shown).




FIG S3 Schematic representation of cloning steps in pVRL2 construction. pVRL1 (A) was digested at the unique NcoI restriction site, to insert the *rrnB* transcriptional terminators (*rrnB* term; red box) to obtain pVRL1a (B). The region including the pVRL1a *lac* promoter (*Plac*, pink), CAP binding site and the first 24 codons of the *lacZα* ORF (Δ *lacZα*; gray) were deleted to obtain pVRL1b (C). An arabinose inducible regulatory element, composed of the *araC* gene and the P_{BAD} promoter (indicated in dark green and brown, respectively) was introduced in pVRL1b, to obtain the expression plasmid pVRL2 (D). Relevant features of plasmids are indicated with different colours: Gm-resistance cassette (green); *nickase*-like gene (cyan); *paaA2*-like antitoxin gene (orange); *parE2*-like toxin gene (light purple); ColE1-like origin of replication (yellow); and *oriAb* (violet). Unique cutter restriction enzymes are in bold. All the genes are reported in scale over the total length of the vector. Image obtained by the Snapgene software (from GSL Biotech; available at snapgene.com).




FIG S4 Arabinose inducible expression of the *gfp* gene under the control of the *araC*- P_{BAD} promoter in plasmid *pVRL2gfp*. Expression of the fluorescent protein Gfp was investigated using confocal microscopy. Six hours after addition of arabinose, *A. baumannii* ATCC19606^T cells carrying *pVRL2gfp* were observed by confocal microscopy. The fluorescence emission upon excitation at 475 nm was used to assess the presence of cell-associated fluorescence (Gfp). Representative images are shown. A Leica SP5 confocal laser scanning microscope equipped with a 63 \times oil immersion objective was used. Scale bar, 50 μ m. DIC, differential interference contrast; Merge, merged DIC and Gfp images.




FIG S5 Minimum Inhibitory Concentration (MIC) of gentamicin on LA for strains carrying the pVRL plasmids. Bacterial suspensions containing *ca.* 5×10^4 CFU were spotted on LA containing different gentamicin (Gm) concentrations (0 to 512 $\mu\text{g/ml}$). The MICs, when available, were determined after 24 hours of incubation at 37°C.




FIG S6 The presence of a toxin-antitoxin (TA) system affects *E. coli* cell morphology without disturbing bacterial growth. (A) Morphology of *E. coli* DH5 α harbouring both pVRL1 Δ *paaA2*-like and pME6032*paaA2*-like plasmids, grown in the presence of IPTG (2 and 0.06 mM), as observed by confocal microscopy. (B) *E. coli* DH5 α and *A. baumannii* ATCC19606^T cells were observed using confocal microscopy. *E. coli* DH5 α cells harbouring pVRL1 showed a filamentous shape, while deletion of TA system (pVRL1 Δ TA) restored the normal morphology. No effect on morphology was observed for *A. baumannii* ATCC19606^T, independently of plasmid carriage. Wild type strains were used as controls. Scale bar: 50 μ m. (C) Growth of *E. coli* DH5 α and *A. baumannii* ATCC19606^T harbouring pVRL1 or pVRL1 Δ TA in LB supplemented with Gm (10 μ g/ml for *E. coli* and 100 μ g/ml for *A. baumannii*). Data are the mean \pm SD of three independent experiments.

Table S1. Primers

Primer	Restriction site	Sequence (5'-3')^a	Use
MCS ori ColE1-like FW	NcoI	CATGCCATGGTTACAATTTCCATTCGCCATT	Amplification of ColE1-like origin, MCS and <i>lacZα</i> from pBS; Sequencing of pVRL1
MCS ori ColE1-like RV	BclI	CTGTGATCACAAGTTTACTCATATATACTTTA	Amplification of ColE1-like origin, MCS and <i>lacZα</i> from pBS; Sequencing of pVRL1
<i>aacC1</i> FW	NcoI	CTACCCATGGTTCGTGATACGCCTATTTTTAT	Amplification of gentamicin resistance cassette from pEX19Gm; Sequencing of pVRL1
<i>aacC1</i> RV	NsiI	CCAATGCATACTTGGTCTGACAATCGATG	Amplification of gentamicin resistance cassette from pEX19Gm; Sequencing of pVRL1
oriAb FW1	-	CAATGAGTAGTCATTTAATTGGC	Sequencing of pWH1277-derived portion of pWH1266 and pVRL1
oriAb FW2	-	GATCGTAGAAATATCTATGATT	Sequencing of pWH1277-derived portion of pWH1266 and pVRL1
oriAb RV	-	GGATTTTAACATTTTGC GTTG	Sequencing of pWH1277-derived portion of pWH1266 and pVRL1
Seq. 1a	-	GAGTTGTTTCGGTAAATTGTCA	Sequencing of pWH1277-derived portion of pWH1266 and pVRL1
Seq. 1b	-	CTAGCCCTTGC GGTTAAGG	Sequencing of pWH1277-derived portion of pWH1266 and pVRL1
Seq. 2	-	TAGATCCTTTTAAATTA AAAATGAA	Sequencing of pVRL1
Seq. 3a	-	TAATCGCTTCCTATGACGTT	Sequencing of pWH1277-derived portion of pWH1266 and pVRL1
Seq. 3b	-	TAAGCGGCTGTATGCAGTG	Sequencing of

Seq. 4	-	AATCATCAATTTCAATAGCTGC	Sequencing of pWH1277-derived portion of pWH1266 and pVRL1
Seq. 5	-	GTTAATTATTCTTACTAATATTATCT	Sequencing of pWH1277-derived portion of pWH1266 and pVRL1
Seq. 6	-	GTTGGGAGTAGGTGGCTAC	Sequencing of pVRL1
Seq. 7	-	GGTTTGCATATTGGGCGCTC	Sequencing of pVRL1
Seq. 8	-	CGGCTATGTCAAAGATGCTG	Sequencing of pWH1277-derived portion of pWH1266 and pVRL1
Seq. 9	-	CAGCCTGTTGCATCTGCTCAT	Sequencing of pWH1277-derived portion of pWH1266 and pVRL1; Verification of correct orientation of <i>rrnB</i> terminators
Seq. 10	-	GGTATCTGCGCTCTGCTG	Sequencing of pVRL1
Seq. 11	-	CATTCATCGCGCTTGCTGCC	Sequencing of pVRL1
Seq. 12	-	GACCACTCCTGCGATGTGTG	Sequencing of pWH1277-derived portion of pWH1266 and pVRL1
<i>rrnB</i> term FW	NcoI	CATGCCATGGTGCCTGGCGGCAGTAGCG	Amplification of <i>rrnB</i> terminators from pEX19Gm
<i>rrnB</i> term RV	NcoI	CATGCCATGGAAACGCAAAAAGGCCATCCG	Amplification of <i>rrnB</i> terminators from pEX19Gm; Verification of correct orientation of <i>rrnB</i> terminators
Δ <i>lacP</i> FW	XhoI	CGCCTCGAGGTCAACGGTATC	Primer flanking <i>lac</i> promoter in pVRL1a used for deletion
Δ <i>lacP</i> RV	NsiI	CCAATGCATCTTTCCAGTCGGGAAACC	Primer flanking CAP binding site in pVRL1a used for deletion

<i>araC</i> P _{BAD} FW	Nsil	CCAATGCATAATGTGCCTGTCAAAT	Amplification of <i>araC</i> and P _{BAD} from miniCTX1- <i>araC</i> -P _{BAD} - <i>tolB</i> and cloning in pVRL1b
<i>araC</i> P _{BAD} RV	XhoI	CCGCTCGAGATTCAGAAGGTTAGCCCCAAA	Amplification of <i>araC</i> and P _{BAD} from miniCTX1- <i>araC</i> -P _{BAD} - <i>tolB</i> and cloning in pVRL1b
<i>trpE</i> prom.	XhoI	CCGCTCGAGTATCTGCTTCACAATCATTAAATGA	Amplification of <i>trpE</i> gene with its endogenous promoter
<i>trpE</i> ATG FW	XhoI	CCGCTCGAGATGACTACATTAGCGCAATTCG	Amplification of <i>trpE</i> gene
<i>trpE</i> RV	PstI	AAA<u>ACTGCAGTC</u>CATAAAATCAATCCGTTTGATG	Amplification of <i>trpE</i> gene
<i>lacZ</i> FW	XhoI	CCGCTCGAGATGACCATGATTACGGATTAC	Amplification of <i>lacZ</i> gene
<i>lacZ</i> RV	PstI	AAA<u>ACTGCAGT</u>TATTTTTGACACCAGACCAACT	Amplification of <i>lacZ</i> gene
<i>tetA</i> FW	XhoI	CCGCTCGAGATGAAATCTAACAATGCGCTCA	Amplification of <i>tetA</i> gene
<i>tetA</i> RV	PstI	AAA<u>ACTGCAGG</u>GAGGTGCCGCCGGCTTC	Amplification of <i>tetA</i> gene
<i>mCherry</i> FW	XhoI	CCTCTCGAGGTGAGCAAGGGCGAGGAG	Amplification of <i>mCherry</i> gene
<i>mCherry</i> RV	EcoRI	CCGGAATTCTCACTTGTACAGCTCGTCC	Amplification of <i>mCherry</i> gene
Zeo1 FW	Nsil	CCAATGCATTTCCTTACGCATCTGTGC	Amplification of zeocin resistance cassette from pCR TM -Blunt II-TOPO [®]
Zeo1 RV	Nsil	CCAATGCATGTGTCAGTCCTGCTCCTCG	Amplification of zeocin resistance cassette from pCR TM -Blunt II-TOPO [®]
Zeo2 FW	KpnI	GGTGGTACCTTTCTCCTTACGCATCTGTGC	Amplification of zeocin resistance cassette from pCR TM -Blunt II-TOPO [®]
Zeo2 Rv	Apal	ACCGGGCCCGTGTGTCAGTCCTGCTCCTC	Amplification of zeocin resistance cassette from pCR TM -Blunt II-TOPO [®]

pVRL1Δ <i>aacC1</i> FW	NsiI	CCTATGCATCTACTTGCATTACAGTTTACGAAC	Primer flanking <i>aacC1</i> gene in pVRL1 used for deletion of Gm resistance cassette
pVRL1Δ <i>aacC1</i> RV	NsiI	CCAATGCATACCAAGTATGCAGCCCCT	Primer flanking <i>aacC1</i> gene in pVRL1 used for deletion of Gm resistance cassette
pVRL2Δ <i>aacC1</i> FW	KpnI	CCGGGTACCCTACTTGCATTACAGTTTACGAAC	Primer flanking <i>aacC1</i> gene in pVRL2 used for deletion of Gm resistance cassette
pVRL2Δ <i>aacC1</i> RV	Apal	ACCGGGCCCACCAAGTATGCAGCCCCT	Primer flanking <i>aacC1</i> gene in pVRL2 used for deletion of Gm resistance cassette
ΔTA FW	-	CTTACTCATGTACTTTGGATTATTTAG	Primer flanking TA system in pVRL1 used for deletion (generation of pVRL1ΔTA)
ΔTA RV	BclI	CTCTGATCAGTTTTTCACTCCAATGTGTTAC	Primer flanking the antitoxin gene <i>paaA2</i> -like system in pVRL1 used for the deletion of the TA system (generation of pVRL1ΔTA) and the deletion of <i>paaA2</i> -like gene (generation of pVRL1Δ <i>paaA2</i> -like)
Δ <i>paaA2</i> -like FW	-	ATGAAGATTGAGTGGACTG	Primer flanking the antitoxin <i>paaA2</i> -like gene in pVRL1 used for the deletion of <i>paaA2</i> -like gene (generation of pVRL1Δ <i>paaA2</i> -like)
<i>paaA2</i> -like FW	EcoRI	CCGGAATTCATGACAGAAGCGACTTTTAC	Amplification of <i>paaA2</i> -like antitoxin gene
<i>paaA2</i> -like RV	SacI	ACCGAGCTCTCCACTCAATCTTCATTCTCG	Amplification of <i>paaA2</i> -like antitoxin gene
<i>aacC1</i> PCN FW	-	GATCTATATCTATGATCTCGC	Determination of pVRL1 copy number in <i>E. coli</i> and <i>A. baumannii</i>

<i>aacC1</i> PCN RV	-	GATCACATAAGCACCAAGCG	Determination of pVRL1 copy number in <i>E. coli</i> and <i>A. baumannii</i>
<i>dxs</i> Ab FW	-	AGTTTGGGATGTGGGACACC	Determination of pVRL1 copy number in <i>A. baumannii</i> . Amplification from nt 195,274 to nt 195,387 encompassing an internal fragment (113 bp) of gene HMPREF0010_01955
<i>dxs</i> Ab RV	-	CTTCTCTGGCTGGGAAAGCA	Determination of pVRL1 copy number in <i>A. baumannii</i> . Amplification from nt 195,274 to nt 195,387 encompassing an internal fragment (113 bp) of gene HMPREF0010_01955
<i>dxs</i> Ec FW	-	CGAGAAACTGGCGATCCTTA	Determination of pVRL1 copy number in <i>E. coli</i> . Amplification from nt 436,807 to nt 436,694 encompassing an internal fragment (113 bp) of gene G6237
<i>dxs</i> Ec RV	-	CTTCATCAAGCGGTTTCACA	Determination of pVRL1 copy number in <i>E. coli</i> . Amplification from nt 436,807 to nt 436,694 encompassing an internal fragment (113 bp) of gene G6237

^aGC clamps are shown in bold; restriction sites are underlined.

Table S2. Comparison of I-TASSER and SWISS-MODEL prediction scores for the ParE2-PaaA2-like toxin-antitoxin system of pWH1277

Predicted protein (ORF)	Accession number of proteins predicted by BLASTX analyses	I-TASSER template (PDB ID; reference)	TM-score ^a	SWISS-MODEL template (PDB ID; reference)	QMEAN ^b
Putative toxin (ORF-3)	WP005166293.1	<i>E. coli</i> ParE2 toxin (5CW7; ref. 1)	0.969	<i>E. coli</i> ParE2 toxin (5CW7; ref. 1)	-1.48
Putative antitoxin (ORF-2)	WP005166297.1	<i>E. coli</i> YafQ antitoxin (4ML0; ref. 2)	0.571	<i>E. coli</i> YafQ antitoxin (4Q2U; ref. 3)	-2.43

^aTM-score is a measure of global structural similarity between query and template protein; the value is comprised between 0 (lowest similarity) and 1 (highest similarity);

^bThe global and per-residue model quality has been assessed using the QMEAN scoring function (4).

Supplementary references

1. Sterckx YG, Jove T, Shkumatov AV, Garcia-Pino A, Geerts L, De Kerpel M, Lah J, De Greve H, Van Melderen L, Loris, R. 2016. A unique hetero-hexadecameric architecture displayed by the *Escherichia coli* O157 PaaA2-ParE2 antitoxin-toxin complex. *J Mol Biol.* 428: 1589-1603.
2. Liang Y, Gao Z, Wang F, Zhang Y, Dong Y, Liu Q. 2014. Structural and functional characterization of *Escherichia coli* toxin-antitoxin complex DinJ-Yafq. *J Biol Chem* 289:21191-21202.
3. Ruangprasert A, Maehigashi T, Miles SJ, Giridharan N, Liu JX, Dunham CM. 2014. Mechanisms of toxin inhibition and transcriptional repression by *Escherichia coli* DinJ-YafQ. *J Biol Chem* 289:20559-20569.
4. Benkert P, Biasini M, Schwede T. 2011. Toward the estimation of the absolute quality of individual protein structure models. *Bioinformatics* 27:343-350.